Isocitrate dehydrogenase‐mutant glioma: Evolving clinical and therapeutic implications
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.31039
Abstract: The metabolic genes isocitrate dehydrogenase 1 (IDH1) and IDH2 are commonly mutated in low‐grade glioma and in a subset of glioblastoma. These mutations co‐occur with other recurrent molecular alterations, including 1p/19q codeletions and tumor suppressor… read more here.
Keywords: glioma; isocitrate dehydrogenase; idh; mutant glioma ... See more keywords
Intraoperative detection of IDH‐mutant glioma using fluorescence lifetime imaging
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Biophotonics"
DOI: 10.1002/jbio.202200291
Abstract: Identifying isocitrate dehydrogenase (IDH)‐mutation and glioma subtype during surgery instead of days later can aid in modifying tumor resection strategies for better survival outcomes. We report intraoperative identification of IDH‐mutant glioma (N = 12 patients)… read more here.
Keywords: idh mutant; mutant glioma; glioma; fluorescence lifetime ... See more keywords
The effects of dabrafenib and/or trametinib treatment in Braf V600-mutant glioma: a systematic review and meta-analysis
Sign Up to like & getrecommendations! Published in 2024 at "Neurosurgical Review"
DOI: 10.1007/s10143-024-02664-x
Abstract: This study aimed to evaluate the effects of dabrafenib and/or trametinib therapy in BRAF v600-mutant glioma treatment. PubMed, the Cochrane Library, EMBASE and Web of Science were searched from inception to Sep 2023. Inclusion criteria… read more here.
Keywords: treatment; dabrafenib trametinib; mutant glioma; v600 mutant ... See more keywords
Multi-institutional study of the frequency, genomic landscape and outcome of IDH-mutant glioma in paediatrics.
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-oncology"
DOI: 10.1093/neuonc/noac132
Abstract: BACKGROUND The incidence and biology of IDH1/2 mutations in pediatric gliomas are unclear. Notably, current treatment approaches by pediatric and adult providers vary significantly. We describe the frequency and clinical outcomes of IDH1/2-mutant gliomas in… read more here.
Keywords: mutant glioma; idh1 mutant; multi institutional; frequency ... See more keywords
INNV-37. REAL-WORLD OUTCOMES AMONG HIGH GRADE IDH1-MUTANT GLIOMA PATIENTS TREATED WITH AN IDH INHIBITOR
Sign Up to like & getrecommendations! Published in 2024 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noae165.0698
Abstract: Isocitrate dehydrogenase (IDH) inhibitors are transforming the treatment of patients with non-enhancing grade 2 IDH-mutant gliomas. Uncertainty remains on the utility of IDH-inhibitors in high-grade IDH-mutant glioma patients that had prior therapies and have progressive… read more here.
Keywords: disease; treatment; high grade; glioma patients ... See more keywords
NIMG-52. ARTIFICIAL INTELLIGENCE-BASED VOLUMETRIC KINETICS FOR EVALUATING TREATMENT RESPONSE IN IDH-MUTANT GLIOMA TREATED WITH IMMUNOTHERAPY
Sign Up to like & getrecommendations! Published in 2024 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noae165.0816
Abstract: Interpretating radiographic findings of glioma patients receiving immunotherapy is challenging. Repeated imaging is often required for clinical decisions, potentially delaying next line of treatment. Here we assess a glioma segmentation AI model to evaluate treatment… read more here.
Keywords: treatment; mutant glioma; response; idh mutant ... See more keywords
P09.03.B ONCOLOGIC AND PATIENT-REPORTED OUTCOMES OF PENCIL-BEAM-SCANNING PROTON BEAM THERAPY FOR CNS WHO G2 AND G3 IDH1-MUTANT GLIOMA: A SINGLE INSTITUTION EXPERIENCE
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf193.294
Abstract: Patients with CNS-WHO G2 and G3 IDH-mutant glioma commonly achieve long survival after chemoradiotherapy. Proton beam therapy (PBT) can be used for this group to reduce the dose to uninvolved brain and, consequently, late toxicity… read more here.
Keywords: proton; therapy; beam; mutant glioma ... See more keywords
RADT-71. REAL-WORLD CHARACTERISTICS OF IDH-MUTANT GLIOMA PATIENTS UNDERGOING REIRRADIATION AT RECURRENCE: A MULTI-INSTITUTIONAL RETROSPECTIVE ANALYSIS
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.0440
Abstract: Limited data guide the treatment of IDH-mutant gliomas at post-radiation recurrence. Current clinical decisions are extrapolated from mixed molecular cohorts, resulting in inconsistent approaches, particularly for lower-grade tumors. Recurrent IDH-mutant gliomas are treated with a… read more here.
Keywords: treatment; radiation; reirradiation; mutant glioma ... See more keywords
CTNI-19. PHASE 2, MULTICENTER, RANDOMIZED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAFUSIDENIB IN PATIENTS WITH HIGH-GRADE ISOCITRATE DEHYDROGENASE 1 (IDH1)-MUTANT GLIOMA
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.0516
Abstract: Isocitrate dehydrogenase (IDH)-mutant gliomas are molecularly and clinically distinct cancers that affect primarily younger adults. Patients with World Health Organization (WHO) Grade 3 or Grade 4 IDH-mutant astrocytoma represent an unmet need because their disease… read more here.
Keywords: idh1 mutant; mutant glioma; safusidenib; phase ... See more keywords
IMG-117. Characterization of recurrent IDH-mutant glioma using multiparametric1H/Hyperpolarized-13C MRI and histopathological analysis
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.1196
Abstract: Isocitrate dehydrogenase (IDH)-mutant gliomas demonstrate metabolic reprogramming and remain challenging to assess using conventional MRI alone. 1H MR spectroscopic imaging (MRSI) of steady-state metabolism and real-time hyperpolarized carbon-13 (HP-13C) MRI of dynamic metabolism are of… read more here.
Keywords: mutant glioma; histopathology; 13c mri; idh mutant ... See more keywords
Abstract 3414: The pan-RAF inhibitor tovorafenib suppresses NF1-mutant glioma through upregulation of FOXO1 and triggering of oncogene-induced senescence
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3414
Abstract: Pediatric low-grade glioma (pLGG) is the most common childhood brain tumor. Patients with pLGG often have significant lifelong disabilities due to the location of the tumor and tumor treatments, including surgery, chemotherapy, and radiation. The… read more here.
Keywords: mutant glioma; tovorafenib; senescence; foxo1 ... See more keywords